Kevin Rouault-Pierre

Kevin Rouault-Pierre serves as a Reader (equivalent to Associate Professor) in Stem Cell Biology at Queen Mary University of London's Centre for Haemato-Oncology, where he leads a research group investigating hematopoietic stem cells and leukemic initiating cells. His work focuses on signal integration in normal and malignant stem cells within blood disorders.

Education:

• Bachelor of Science (BSc)
• Master of Science (MSc)
• Doctor of Philosophy (PhD)

His research centers on myelodysplastic syndromes (MDS) and leukemia pathogenesis, examining how intrinsic factors like SF3B1 mutations and extrinsic elements such as metabolic alterations disrupt erythropoiesis and reshape bone marrow microenvironments. Key themes include Cell Signalling, Disease Modelling, and Metabolism in cancer contexts, with particular emphasis on targeting tumour cells through metabolic interventions. His group employs preclinical models to bridge basic mechanisms with therapeutic applications.

Analysis of his 2013-2023 publications reveals consistent translational focus: metabolic pathways (Vitamin B5/succinyl-CoA) for ineffective erythropoiesis, DNA repair defects (ERCC6L2), and splicing factor mutations (SF3B1) in MDS. His work demonstrates progression from foundational stem cell biology (2013-2016) toward targeted metabolic therapies (2022-2023), highlighting evolving strategies to modulate the bone marrow microenvironment.

No scientific awards are documented in the source material.

He secures significant funding including CRUK Early Detection Awards (2023-2026), Barts Charity Project Grants (2022-2025), and European Hematology Association Collaborative Grants (2024-2025). While specific students aren't listed, his Group Leader role implies active mentorship of researchers within his laboratory.

His team operates within Queen Mary's Centre for Haemato-Oncology, collaborating through memberships in the British Society of Haematology, European Haematology Association, and Société Française d'Hématologie to advance translational research in blood cancers.